Filtered library · Theme
Oncology & immunology theme · 63 dossiers
Dossiers in the Oncology & immunology theme cluster — 63 names moving on shared catalysts.
Theme runProduced by the theme run on 9 September 2026, maturing.
All 63 are dated research with a published kill line — the level named in advance that would prove the call wrong.
All dossiers PSNL Personalis, Inc. fresh HIGH The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus… RVMD Revolution Medicines, Inc. fresh HIGH Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to… DCTH Delcath Systems, Inc. fresh MEDIUM Delcath Systems’ self-funded liver-treatment expansion must sustain its raised revenue outlook. Confirmation requires maintained $104–108 million guidance at the next quarterly report and a weekly close above $17.36 before a weekly close… IOVA Iovance Biotherapeutics, Inc. fresh MEDIUM Iovance Biotherapeutics' Amtagvi ramp supports a higher 2026 revenue outlook; a company-issued range above $350–370 million by 2026-09-30 would confirm it. An unchanged range or a missed update deadline would invalidate the revision thesis. NVCT Nuvectis Pharma, Inc. MEDIUM Nuvectis Pharma’s expanded-pipeline valuation depends on US development of its Haisco compounds. The case requires announced IND submissions for both assets and a weekly close above the $28.53 trailing high by 2026-12-31, before a weekly… ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… SMMT Summit Therapeutics Inc. fresh MEDIUM Summit Therapeutics’ ivonescimab thesis is that quantified survival evidence converts into US approval by 2026-11-14 before a weekly close below $15.00. September’s disclosures strengthen the clinical case, but the global trial’s primary… VSTM Verastem, Inc. MEDIUM Verastem’s commercial launch supports a VS-7375 clinical revaluation thesis, tested by the newly scheduled 2026-10-14 efficacy update. The case requires reported tumor responses and a daily close above the 2026-09-02 reference close of… ZLAB Zai Lab Limited MEDIUM Zai Lab's global drug-development re-rating depends on October's zoci data leading to first-line lung-cancer Phase 3 initiation by 2026-12-31. The case requires those milestones before a weekly close below $22; the partnered ALKIVIA… CLYM Climb Bio, Inc. fresh LOW Climb Bio's re-rating depends on Q4 2026 budoprutug patient data establishing clinical benefit. Recovery of the $17.84 adjusted annual high would confirm the price leg; a weekly close below $13.30 or a delay beyond the guided clinical… IMMX Immix Biopharma, Inc. LOW Immix Biopharma’s NXC-201 story hinges on late-September data extending the reported 95% response rate across more patients. Confirmation requires that update by 2026-09-30 before a weekly close below $11.00; company language does not… INBX Inhibrx Biosciences, Inc. LOW Inhibrx Biosciences’ advance prices HexAgon clinical success and a Phase 3 start within the guided quarter. The 2026-09-08 results and September start confirmation test that case; a weekly close below $104 or reported primary-endpoint… KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… XNCR Xencor, Inc. LOW Xencor’s post-settlement re-rating depends on October XmAb819 data supporting a pivotal-dose choice and the planned 2027 study. A weekly close below $23.34 or withdrawal of that timetable invalidates the continuation case. TNGX Tango Therapeutics, Inc. fresh LOW Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)… NUVL Nuvalent, Inc. fresh SUPREME Nuvalent’s independent equity story ended with GSK’s $124-per-share acquisition on 2026-07-15. The 2026-09-14 zidesamtinib update advances GSK’s clinical portfolio; only an official restoration of the former listed equity would reopen the… BMY Bristol-Myers Squibb Co. fresh MEDIUM Post-guidance-reset re-rate printed a new 52-week high of $68.09 before the 2026-09-04 close of $66.82, but the first negative company headline of the leg — the zola-cel autoimmune CAR-T enrollment pause confirmed 2026-08-31 — arrived with… CGEM Cullinan Therapeutics, Inc. fresh MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… CSTL Castle Biosciences, Inc. fresh MEDIUM Castle Biosciences’ recovery rests on TissueCypher sustaining its growth plan; the next quarterly results must preserve revenue and test-volume guidance. Management’s unchanged outlook at the 2026-09-15 Baird conference supports the case,… DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… FTRE Fortrea Holdings Inc. fresh MEDIUM Fortrea’s margin-repair recovery requires backlog growth and preservation of the $205 million full-year adjusted-EBITDA floor at the next quarterly report. The September 18 shelf recovery supports the case, which a weekly close below… GERN Geron Corporation fresh MEDIUM The leg is a self-funding commercial ramp, not the myelofibrosis binary: Q2 RYTELO revenue $57.5M (+11% QoQ), quarterly cash draw down to ~$14M on $326.9M, FY guide $220–240M reiterated at the mid-to-high end. The 2026-09-02 release added… GH Guardant Health, Inc. fresh MEDIUM Guardant Health’s renewed advance prices broader Shield coverage becoming screening revenue. The next quarterly screening result must exceed Q2’s $52.9 million, reported on 2026-07-30; a weekly close below the 2026-09-04 reference close of… ICLR ICON plc MEDIUM ICON plc’s restatement-discount recovery depends on bookings sustaining its earnings outlook. A weekly close above the August reference of $172.23 and unchanged guidance at the next quarterly disclosure would confirm renewed recovery; a… IDYA IDEAYA Biosciences, Inc. fresh MEDIUM IDEAYA Biosciences' darovasertib filing and expansion trials underpin a recovery thesis. Confirmation requires a weekly close above the $42.48 reference high and NDA completion by 2026-12-31 before a weekly close below $34; the October… ONC BeOne Medicines Ltd. fresh MEDIUM BeOne Medicines’ BRUKINSA growth supports a renewed-high thesis, but September price action has not confirmed it. A weekly close above the supplied $377.47 high would establish the price outcome; a weekly close below $326 would invalidate… RLYB Rallybio Corporation fresh MEDIUM Rallybio’s Avenzo merger thesis combines a cash distribution with residual oncology exposure; completion and a declared distribution would establish the outcome. A weekly close below $14 invalidates the price case, while failure to close… VCYT Veracyte, Inc. fresh MEDIUM Sell-side is now chasing a move it missed: VCYT broke to a 52-wk high $60.91 (closed $59.13 on 2026-07-17, +124% YoY) as Piper initiated Overweight $66 (07-15) and Canaccord lifted a Hold PT $42→$60. Fundamentals still accelerating (Q1 rev… ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… ZYME Zymeworks Inc. fresh MEDIUM Zymeworks’ Ziihera approval supports royalty growth; Q3 2026 royalties must exceed Q2’s $1.8 million to confirm the next commercial step. A weekly close below $25 invalidates the market case before that confirmation. AKTS Aktis Oncology, Inc. LOW Aktis Oncology's radiopharmaceutical story needs September conference attention to restore the August breakout. A weekly close above the 2026-08-28 close of $25.78 would confirm recovery, while a weekly close below $22 would invalidate the… ANAB AnaptysBio, Inc. fresh LOW AnaptysBio’s Jemperli rights-reversion thesis turns on a written Chancery judgment; the September 25 brief advances the case without settling it. A judgment granting reversion before a weekly close below $52 would establish the thesis… AUTL Autolus Therapeutics plc LOW Autolus Therapeutics’ AUCATZYL growth story lost price confirmation when the 2026-09-11 close breached the published $2.05 weekly threshold. A recovery case requires a weekly reclaim above $2.05 and delivery against the $140–150 million… BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… CADL Candel Therapeutics, Inc. fresh LOW Candel Therapeutics’ recovery case requires a weekly reclaim of $11.80 and its planned Q4 2026 prostate-cancer filing before a daily close below $10.85. The September 18 close already invalidated the previous momentum thesis. CLDX Celldex Therapeutics, Inc. LOW Celldex Therapeutics’ barzolvolimab case requires both Phase 3 CSU trials to meet their primary efficacy endpoints by 2026-10-31 before a weekly close below $35. The 2026-09-11 close of $36.90 leaves the structural case unresolved ahead of… CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… CRVS Corvus Pharmaceuticals, Inc. LOW Corvus Pharmaceuticals’ soquelitinib recovery case requires a weekly close above the August 28 close of $14.16 before a weekly close below $12.50. Angel’s eczema results, guided on August 6 to late 2026, remain the next clinical test;… DNTH Dianthus Therapeutics, Inc. LOW Dianthus Therapeutics’ claseprubart re-rating depends on supportive December clinical evidence and a dated pivotal readout. The price case requires a weekly close above $115.96 by 2026-12-31 before a weekly close below $100 invalidates it. ELVN Enliven Therapeutics, Inc. LOW Enliven Therapeutics’ re-rating case depends on starting the pivotal ELVN-001 trial within its guided second half of 2026. Disclosed initiation and a weekly close above the $61.15 high recorded on 2026-09-11 would confirm the case before a… ERAS Erasca, Inc. LOW FDA Fast Track for ERAS-0015 in metastatic pancreatic (2026-08-24) landed on 16.4x average volume for a -0.17% close; J.P. Morgan then marked to a street-high $33 on 2026-08-27 while the 2026-08-28 close was $18.03 against a $23.5… EVH Evolent Health, Inc fresh LOW The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which… GLUE Monte Rosa Therapeutics, Inc. fresh LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… ILMN Illumina, Inc. LOW Illumina’s NovaSeq X recovery has a September 21 index catalyst, but price confirmation remains absent. A weekly close above the $227.69 reference high and delivery against July’s third-quarter revenue outlook would validate the case; a… IMRX Immuneering Corporation fresh LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… IMVT Immunovant, Inc. fresh LOW Immunovant’s recovery case depends on IMVT-1402 clinical progress restoring the market’s $44.96 reference high by December 31, 2026. A weekly close below $35 invalidates the case; the September 18 three-month decline and undated clinical… JBIO Jade Biosciences, Inc. fresh LOW Jade Biosciences' JADE101 dosing story supports a conditional recovery case, but patient efficacy remains unresolved. A weekly close above the lost July $21 shelf would establish price repair; a weekly close below the June offering… LEGN Legend Biotech Corporation fresh LOW In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst… MEDP Medpace Holdings, Inc. fresh LOW Bookings-inflection leg (Q2 awards $795.7M, +28.2% YoY, 1.13x book-to-bill, FY26 guide raised 2026-07-22) unchanged on fundamentals, but the tape has given back part of the August recovery — $600.65 on 08-28 to $591.29 on 09-04 — while the… MGNX MacroGenics, Inc. fresh LOW MacroGenics' MGC026 revaluation thesis turns on the 2026-10-23 cancer-data presentation. Cohort-level response and durability evidence followed by a weekly close above $4.86 would confirm the case; a weekly close below $3.90 invalidates it. NRIX Nurix Therapeutics, Inc. fresh LOW Nurix Therapeutics' Roche-backed bexobrutideg story needs renewed clinical evidence after September's conference window. A weekly close above the $27.79 reference high would confirm the price leg; a weekly close below $24 would invalidate… NVCR NovoCure Limited fresh LOW NovoCure Limited’s commercial-inflection thesis requires another revenue-guidance increase and positive adjusted EBITDA at the next quarterly report. A weekly close below $15.40 invalidates the July repricing; unchanged guidance would fail… ORIC Oric Pharmaceuticals, Inc. fresh LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… PRLD Prelude Therapeutics Incorporated fresh LOW Prelude Therapeutics remains an Incyte option-exercise story: the $100 million fee would resolve the case positively if exercise precedes a weekly close below $4.75. September trial clearance adds pipeline progress, but the… RLAY Relay Therapeutics, Inc. fresh LOW Relay Therapeutics' zovegalisib recovery case requires quantified Phase 3 enrollment progress by year-end 2026 and a weekly close above $20.75. A weekly close below $17.50 invalidates the case; the September 18 close of $18.84 has not… RLMD Relmada Therapeutics, Inc. fresh LOW Relmada Therapeutics’ NDV-01 re-rating thesis was invalidated by the $4.12 weekly close on 2026-09-18, below its published $4.25 shelf. A recovery above the March financing level and an announced IND submission would provide evidence for a… SLS SELLAS Life Sciences Group, Inc. fresh LOW Borrowed sector re-rate has cooled: SLS closed $13.86 on 2026-09-04, 10.3% under the 2026-08-21 high of $15.46, RSI back to 54.1, while REGAL's last published count is still 78 of 80 from 2026-05-11 and BMF Capital's 2026-08-31 short… STRO Sutro Biopharma, Inc. fresh LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… STTK Shattuck Labs, Inc. fresh LOW Shattuck Labs' receptor-blocking antibody story has advanced to an open Crohn's trial, according to management on September 8. The near-term recovery case requires a weekly close above September 4's $6.79 reference close before a weekly… TGTX TG Therapeutics, Inc. LOW The catalyst leg is spent; what is left is whether the $46–48 shelf holds through a two-month news vacuum into year-end subcutaneous Phase 3 topline. URGN UroGen Pharma Ltd. LOW UroGen Pharma’s ZUSDURI launch-growth thesis requires third-quarter revenue above the second quarter’s $50.4 million before a weekly close below $40 invalidates the structure. The confirmed 2026-09-15 conference adds management exposure,… VIR Vir Biotechnology, Inc. fresh LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… VOR Vor Biopharma Inc. LOW Vor Biopharma’s telitacicept pivot depends on positive global Phase 3 results within its first-half 2027 guidance window. The recovery thesis fails if a weekly close below $20 occurs first, while a failed endpoint or delayed results…